These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 21297495

  • 1. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M.
    Bratisl Lek Listy; 2005 Apr; 106(12):407-11. PubMed ID: 16642666
    [Abstract] [Full Text] [Related]

  • 3. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
    Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW.
    Br J Pharmacol; 2008 Mar; 153(5):947-55. PubMed ID: 18084312
    [Abstract] [Full Text] [Related]

  • 4. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q, Larouche I, Schiffrin EL.
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [Abstract] [Full Text] [Related]

  • 5. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).
    McKinnell RM, Fatheree P, Choi SK, Gendron R, Jendza K, Olson Blair B, Budman J, Hill CM, Hegde LG, Yu C, McConn D, Hegde SS, Marquess DG, Klein U.
    ACS Med Chem Lett; 2019 Jan 10; 10(1):86-91. PubMed ID: 30655952
    [Abstract] [Full Text] [Related]

  • 6. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL.
    J Hypertens; 2008 Feb 10; 26(2):322-33. PubMed ID: 18192847
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug 10; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 8. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q, Touyz RM, Schiffrin EL.
    J Hypertens; 2002 May 10; 20(5):899-907. PubMed ID: 12011651
    [Abstract] [Full Text] [Related]

  • 9. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR.
    Am J Hypertens; 1998 Mar 10; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC.
    J Hypertens Suppl; 1999 Feb 10; 17(1):S37-43. PubMed ID: 10340842
    [Abstract] [Full Text] [Related]

  • 12. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.
    J Pharmacol Exp Ther; 2004 Jun 10; 309(3):1141-7. PubMed ID: 14769834
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.
    J Pharmacol Exp Ther; 2005 Dec 10; 315(3):1306-13. PubMed ID: 16144980
    [Abstract] [Full Text] [Related]

  • 14. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M.
    Hypertension; 2002 Sep 10; 40(3):266-72. PubMed ID: 12215465
    [Abstract] [Full Text] [Related]

  • 15. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1995 Jan 10; 272(1):343-51. PubMed ID: 7815350
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May 10; 47(5):604-12. PubMed ID: 9205773
    [Abstract] [Full Text] [Related]

  • 17. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF, Castano C, Maupas E, Mugniot A, Darblade B, Gourdy P, Michel JB, Bayard F.
    Atherosclerosis; 2001 Apr 10; 155(2):291-5. PubMed ID: 11254898
    [Abstract] [Full Text] [Related]

  • 18. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI.
    Am J Hypertens; 2000 Oct 10; 13(10):1110-6. PubMed ID: 11041166
    [Abstract] [Full Text] [Related]

  • 19. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.
    Clin Sci (Lond); 2003 Sep 10; 105(3):339-45. PubMed ID: 12741953
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z.
    Clin Sci (Lond); 2003 Apr 10; 104(4):341-7. PubMed ID: 12653675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.